Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Transgender hormone therapy (male-to-female) to a higher boost in plasma estradiol levels; however, the long-term side effects haven’t been studied and the safety of this route is unclear. As with any pharmacological or hormone therapy, there are potential side effects, which in the case of transgender hormone therapy include changes in sexual functioning. These have the ability to significantly impact sexual functioning, either directly or indirectly through the various side effects, such as cerebrovascular disorders, obesity, and mood fluctuations. In addition, some research has found an onset of diabetes following feminizing hormone therapy, which impairs sexual response. Whatever route an individual and their doctor